Zimbabwe has turned down a significant US health deal worth $367m (272 million pounds) over five years because of the United States' request for sensitive biological samples.
This move came to light after a official document dated December was leaked, revealing that Head of State Emmerson Mnangagwa deemed the arrangement was "lopsided".
An official spokesperson has since clarified that the United States was requesting biological samples for research and commercial gain while was unwilling to share the resulting advantages from future vaccines.
"We are forced to start the difficult and regrettable task of ending our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had provided over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has called for further negotiations to secure a agreement suitable to all parties so the country's critical HIV programme can proceed.
Broader Background
This development follows a comparable case in neighbouring Kenya, where a high court suspended a related health funding agreement following legal challenges were raised about the security of citizens' health data.
After resuming the presidency last year, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
The agency had administered aid for the US government, but Trump claimed its expenditure was "wasteful" and his government was seeking government-to-government deals to enhance transparency and accountability.
Based on statements, 16 African countries have to date agreed to similar agreements, representing over $18.3bn of fresh investment.
Details of the Declined Agreement
The funds for Zimbabwe would have funded "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this cooperation would have delivered extraordinary benefits for Zimbabwean communities, particularly the 1.2 million presently on antiretroviral therapy through American-funded programmes," the Ambassador added.
However, official spokesman Nick Mangwana maintained the proposed deal was "unequal".
"Our nation was requested to provide its genetic material and health information indefinitely, with no equivalent guarantee of access to any medical innovations – like new medicines or tests – that could be developed from that provided information," he stated.
"In essence, our nation would supply the basic resources for medical research with no certainty that the end products would be accessible to our citizens should a future disease outbreak arise."
National Interest and International Frameworks
Mangwana further noted that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral deals were upending structures previously set up via the global health agency.
Mangwana cited its Pathogen Access and Benefit Sharing system created to deal with potential pandemics.
"This system is designed to guarantee that when a nation provides its samples, the benefits – including vaccines and treatments – are shared equitably, not commercialised exclusively by those with the capability to develop them."
The government's concerns regarding the US deal "should not be misconstrued as opposition to America," he added.
"We encourage ongoing dialogue with our American counterparts on how subsequent collaboration might be structured in a way that respects the sovereignty and dignity of both nations."
Health Experts Response
A leading public health body stated it recognised the government's concerns, but recommended that talks need to persist given that much of the nation's Aids initiatives depended on external financing.
"If technical issues exist, such as those relating to data governance or agreement terms, these can often be addressed via detailed discussion and mutually agreed protections," it commented.
The halted deal underscores the ongoing tensions between receiving much-needed international aid and safeguarding national sovereignty in an increasingly interconnected world.